Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
12:45pm, Thursday, 23'rd Jan 2025
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - JNJ
10:30am, Thursday, 23'rd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ
Lost Money on Johnson & Johnson(JNJ)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
06:01am, Thursday, 23'rd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab demonstrated a sustained reduction in
This Is 1 of the Healthiest High-Yielding Dividend Stocks You'll Find
05:08am, Thursday, 23'rd Jan 2025
Johnson & Johnson (JNJ -1.94%) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62 years in a row.
Earnings Picture Remains Strong: A Closer Look
07:05pm, Wednesday, 22'nd Jan 2025
The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the com
Earnings Picture Remains Strong: A Closer Look
07:05pm, Wednesday, 22'nd Jan 2025
The picture emerging from the 2024 Q4 earnings season is one of strength and improving outlook, with the companies not only coming ahead of estimates but also providing reassuring guidance for the com
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earnings
04:51pm, Wednesday, 22'nd Jan 2025
On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson's nasal spray, Spravato (esketamine), to treat major depressive disorder.
ATTENTION Johnson & Johnson Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
03:30pm, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible
3-Stock Lunch: Netflix, Johnson & Johnson, Travelers
03:28pm, Wednesday, 22'nd Jan 2025
Sarat Sethi, DCLA managing partner, joins 'Power Lunch' to discuss stock plays for three stocks.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
03:00pm, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advised to
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
12:24pm, Wednesday, 22'nd Jan 2025
Johnson & Johnson's Q4 2024 earnings missed EPS expectations but broadly met revenue targets; full-year 2024 showed 4.3% sales growth and $5.79 EPS. Despite short-term challenges, including Stelara's
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
12:15pm, Wednesday, 22'nd Jan 2025
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
12:09pm, Wednesday, 22'nd Jan 2025
Johnson & Johnson (NYSE:JNJ ) Q4 2024 Earnings Conference Call January 22, 2025 8:00 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Ex
